EDEN
PRAIRIE, Minn., May 19, 2022
/PRNewswire/ -- NeuroOne Medical Technologies Corporation
(NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical
technology company focused on improving surgical care options and
outcomes for patients suffering from neurological disorders, today
announced that it will present at the H.C. Wainwright Global
Investment Conference being held May 23-26,
2022 virtually and in Miami,
Florida. NeuroOne will present Wednesday, May 25, 2022, from 3:30 PM - 4:00 PM ET, and the presentation will
be available on-demand via webcast.
Details of NeuroOne's presentation are as follows:
H.C. Wainwright
Global Investment Conference
|
Presentation date and
time:
|
Wednesday, May 25,
2022; 3:30 p.m. ET
|
Location:
|
Online and at the
Fontainebleau Miami Beach Hotel, Miami Beach, Florida
|
Registration:
|
Visit the conference
website to register for either in-person or virtual
attendance
|
Webcast:
|
Available here at the
time of presentation
|
Webcast
Replay:
|
Available for 90
days
|
NeuroOne Chief Executive Officer Dave
Rosa will discuss the Company's progress in developing and
commercializing minimally invasive and
high-definition/high-precision solutions for neurologic conditions
such as epilepsy, Parkinson's disease, dystonia, and essential
tremors, as well as chronic pain from failed back surgeries. These
solutions include minimally invasive thin-film Evo® Cortical
Electrodes that have the potential to reduce costs,
hospitalizations, and surgical procedures and improve patient
outcomes.
About NeuroOne® Medical Technologies
Corporation
NeuroOne is a medical technology company focused
on the development and commercialization of minimally invasive and
high-definition/high-precision solutions for epilepsy, Parkinson's
disease, dystonia, essential tremors, and chronic pain due to
failed back surgeries. A combination recording and RF ablation
technology is currently under development. In addition, NeuroOne is
currently testing its electrodes for long term stimulation. The
Company is also investigating the potential application of its
technology for artificial intelligence and machine learning.
Visit n1mtc.com.
Forward Looking Statements
This press release may
include forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Except for
statements of historical fact, any information contained in this
presentation may be a forward–looking statement that reflects the
Company's current views about future events and are subject to
known and unknown risks, uncertainties and other factors that may
cause our actual results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some
cases, you can identify forward–looking statements by the words or
phrases "may," "might," "will," "could," "would," "should,"
"expect," "intend," "plan," "objective," "anticipate," "believe,"
"estimate," "predict," "project," "potential," "target," "seek,"
"contemplate," "continue, "focused on," "committed to" and
"ongoing," or the negative of these terms, or other comparable
terminology intended to identify statements about the future.
Forward–looking statements may include statements regarding
potential of our technology to reduce the number of
hospitalizations, surgical procedures and reduce costs. Although
the Company believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our technology will not perform as expected
based on results of our pre-clinical testing; uncertainties
inherent in the development process of our technology; risks
related to changes in regulatory requirements or decisions of
regulatory authorities; risks that we may not have accurately
estimated the size and growth potential of the markets for our
technology; and other risks and uncertainties related to market and
other conditions, the impact of general economic, industry or
political conditions in the United States or
internationally and those described under the heading "Risk
Factors" in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of the press release and the Company undertakes no obligation
to revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-its-breakthrough-technology-for-monitoring-neural-activity-at-the-hc-wainwright-global-investment-conference-on-may-25-301551007.html
SOURCE NeuroOne Medical Technologies Corporation